EGFR and non-small cell lung carcinoma: Studies showed that erlotinib, gefitinib, afatinib, and other epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) could effectively improve the objective response rate and overall survival of NSCLC patients with EGFR mutations (including the deletion of exon 19 and the single point mutation L858R in exons 18-21).